FDA set to review Sanofi’s isatuximab for multiple myeloma
Multiple myeloma is the second most common hematologic malignancy, affecting more than 138,0002 people worldwide.
Read More
Tag: RRMM
Xpovio combo bags FDA approval for refractory multiple myeloma
The application was also granted Fast Track designation, and Xpovio received Orphan Drug designation.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
